Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients with Autosomal Dominant Polycystic Kidney Disease
2017-004115-39Phase 4Completed
- Sponsor
- Nordsjællands Hospital
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Nordsjællands Hospital. Primary endpoint: Change in total kidney volume. Started Dec 2017; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2017-004115-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004115-39.